Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $213.85 in the prior trading day, Abbvie Inc (NYSE: ABBV) closed at $212.25, down -0.75%. In other words, the price has decreased by -$0.75 from its previous closing price. On the day, 5.41 million shares were traded. ABBV stock price reached its highest trading level at $214.39 during the session, while it also had its lowest trading level at $210.81.
Ratios:
Our goal is to gain a better understanding of ABBV by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 67.45 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.01. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.66. In the meantime, Its Debt-to-Equity ratio is 20.40 whereas as Long-Term Debt/Eq ratio is at 18.36.
On December 05, 2024, Daiwa Securities Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $180.
Leerink Partners Upgraded its Market Perform to Outperform on November 22, 2024, while the target price for the stock was maintained at $206.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’25 when Reents Scott T sold 17,644 shares for $212.34 per share. The transaction valued at 3,746,527 led to the insider holds 11,577 shares of the business.
Reents Scott T bought 17,644 shares of ABBV for $3,746,628 on Mar 14 ’25. On Feb 28 ’25, another insider, GONZALEZ RICHARD A, who serves as the Director of the company, sold 92,460 shares for $205.11 each. As a result, the insider received 18,964,471 and left with 395,097 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 377520586752 and an Enterprise Value of 437067153408. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 88.75, and their Forward P/E ratio for the next fiscal year is 15.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.78. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.65 while its Price-to-Book (P/B) ratio in mrq is 112.68. Its current Enterprise Value per Revenue stands at 7.758 whereas that against EBITDA is 16.677.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.53, which has changed by 0.19577467 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $218.66, while it has fallen to a 52-week low of $153.58. The 50-Day Moving Average of the stock is 9.95%, while the 200-Day Moving Average is calculated to be 14.45%.
Shares Statistics:
The stock has traded on average 6.05M shares per day over the past 3-months and 5868800 shares per day over the last 10 days, according to various share statistics. A total of 1.77B shares are outstanding, with a floating share count of 1.76B. Insiders hold about 0.11% of the company’s shares, while institutions hold 73.55% stake in the company. Shares short for ABBV as of 1740700800 were 18506353 with a Short Ratio of 3.06, compared to 1738281600 on 18931401. Therefore, it implies a Short% of Shares Outstanding of 18506353 and a Short% of Float of 1.05.
Dividends & Splits
In the trailing 12 months, ABBV’s forward annual dividend rate was 6.29, compared to 6.29 this year. Against a Trailing Annual Dividend Yield of 0.02941314The stock’s 5-year Average Dividend Yield is 4.04.
